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OBJECTIVE — Coffee consumption has been linked to detrimental acute metabolic and
hemodynamic effects. We investigated coffee consumption in relation to risk of CVDs and
mortality in diabetic men.
RESEARCH DESIGN AND METHODS — We conducted a prospective cohort study
including 3,497 diabetic men without CVD at baseline.
RESULTS — Afteradjustmentforage,smoking,andothercardiovascularriskfactors,relative
risks (RRs) were 0.88 (95% CI 0.50–1.57) for CVDs (P for trend  0.29) and 0.80 (0.41–1.54)
for all-cause mortality (P for trend  0.45) for the consumption of 4 cups/day of caffeinated
coffee compared with those for non–coffee drinkers. Stratiﬁcation by smoking and duration of
diabetes yielded similar results. RRs for caffeine intake for the highest compared with the lowest
quintilewere1.02(0.70–1.47;Pfortrend0.96)forCVDsand0.96(0.64–1.44;Pfortrend
0.69) for mortality.
CONCLUSIONS — These data indicate that regular coffee consumption is not associated
with increased risk for CVDs or mortality in diabetic men.
Diabetes Care 32:1043–1045, 2009
C
offee drinking is widespread across
the world and has been linked with
both beneﬁcial and harmful effects
on biological markers of cardiovascular
disease (CVD) (1). Recently, caffeine has
been reported to have acute detrimental ef-
fects on glucose tolerance in diabetes (2).
Whereas most prospective studies have
suggestedthatcoffeeconsumptionisnotas-
sociatedwithincreasedriskforCVDingen-
eral population (3,4), data among diabetes
are sparse (5). Therefore, we prospectively
examined the relationship between coffee
and coronary heart disease (CHD), stroke,
and mortality among men with type 2 dia-
betes in the Health Professionals Follow-up
Study (HPFS).
RESEARCH DESIGN AND
METHODS— The HPFS is a prospec-
tive cohort study of 51,529 male health
professionals aged 40–75 years in 1986.
In this study, after excluding participants
with CVDs or cancer at baseline, 3,497
men remained who reported a diagnosis
of type 2 diabetes on any questionnaire
from 1986 to 2004.
Assessment of coffee consumption
Coffee intake was assessed using a semi-
quantitative frequency questionnaire sent
to the participants in 1986, 1990, 1994,
1998,and2002.Thevalidityandreliabil-
ity of the frequency questionnaire has
previously been described (6). We also
assessed total caffeine intake (7).
Ascertainment of end points
The end points were incident CHD (de-
ﬁned as nonfatal myocardial infarction or
fatal CHD), stroke, and mortality. The di-
agnosis of outcomes has previously been
described (4). Brieﬂy, myocardial infarc-
tion was conﬁrmed if it met the criteria of
the World Health Organization of symp-
tomsandthepatient’srecordsshoweddi-
agnostic electrocardiographic changes or
elevated cardiac enzyme levels. Stroke
was conﬁrmed by medical records ac-
cording to the criteria of the National
SurveyofStroke,whichdeﬁneitasacon-
stellation of neurological deﬁcits, sudden
or rapid in onset, lasting at least 24 h or
until death. Deaths were reported by next
of kin or the postal system or ascertained
through the National Death Index.
Statistical analysis
Cox proportional hazards regression was
used to investigate the association be-
tween coffee consumption and incidence
of cardiovascular events and all-cause
mortality. Multivariable models were ad-
justedforage,smokingstatus,BMI,phys-
ical activity, alcohol intake, parental
history of myocardial infarction, hyper-
tension, hypercholesterolemia, duration
of diabetes, hypoglycemic therapy, and
dietary factors (total energy intake; use of
multivitaminandvitaminEsupplements;
polyunsaturated, saturated, and trans fat
intake;glycemicload;andcerealﬁberand
folate intake) using categorical variables.
The median value of each category of cof-
fee consumption was modeled as a con-
tinuous variable to test for linear trends.
All analyses were performed with SAS
software(version8.2;SASInstitute,Cary,
NC).
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DIABETES CARE, VOLUME 32, NUMBER 6, JUNE 2009 1043Table 1—RRs (95% CI) for CVDs and total mortality by caffeinated coffee consumption and total caffeine intake among men with type 2
diabetes (1986–2004)
Caffeinated coffee consumption (cups)
1/month 1/month–4/week 5–7/week 2–3/day 4/day P for trend
Total cardiovascular events
Person-years 5,489 5,184 7,250 4,855 1,289
n 110 90 144 72 19
Age and smoking adjusted 1.0 0.83 (0.63–1.01) 0.95 (0.74–1.22) 0.73 (0.54–0.98) 0.71 (0.43–1.17) 0.07
Multivariable I† 1.0 0.72 (0.53–1.00) 0.94 (0.70–1.26) 0.65 (0.45–0.92) 0.86 (0.50–1.50) 0.27
Multivariable II‡ 1.0 0.77 (0.53–1.10) 0.93 (0.67–1.28) 0.66 (0.45–0.97) 0.88 (0.50–1.57) 0.29
CHD
n 86 64 106 54 14
Age and smoking adjusted 1.0 0.75 (0.54–1.04) 0.88 (0.66–1.18) 0.70 (0.49–0.98) 0.67 (0.37–1.18) 0.11
Multivariable I† 1.0 0.61 (0.41–0.89) 0.89 (0.63–1.24) 0.60 (0.40–0.91) 0.73 (0.38–1.42) 0.26
Multivariable II‡ 1.0 0.63 (0.41–0.97) 0.90 (0.62–1.31) 0.66 (0.42–1.02) 0.81 (0.41–1.62) 0.45
Stroke
n 24 26 38 18 5
Age and smoking adjusted 1.0 1.12 (0.64–1.96) 1.20 (0.72–2.02) 0.83 (0.45–1.54) 0.88 (0.33–2.35) 0.42
Multivariable I† 1.0 1.16 (0.62–2.17) 1.16 (0.63–2.13) 0.78 (0.37–1.64) 1.34 (0.48–3.78) 0.75
Multivariable II‡ 1.0 1.15 (0.58–2.27) 0.97 (0.51–1.86) 0.63 (0.29–1.36) 0.97 (0.33–2.85) 0.31
All-cause mortality
Person-years 5,555 5,240 7,334 4,901 1,301
Deaths (n) 127 115 173 98 25
Age and smoking adjusted 1.0 0.90 (0.70–1.16) 0.92 (0.73–1.16) 0.90 (0.69–1.17) 0.86 (0.56–1.33) 0.52
Multivariable I† 1.0 0.76 (0.55–1.06) 0.96 (0.71–1.30) 0.72 (0.50–1.04) 0.72 (0.39–1.31) 0.24
Multivariable II‡ 1.0 0.69 (0.47–1.02) 0.89 (0.63–1.26) 0.71 (0.47–1.06) 0.80 (0.41–1.54) 0.45
Quintiles of caffeine intake (mg/day) P for trend
110 110–203 204–316 317–450 450
Median intake (mg/day) 48 160 238 379 724
Total CVD events
Person-years 4,768 4,835 4,801 4,845 4,818
n 90 84 104 75 82
Age and smoking adjusted 1.0 0.94 (0.70–1.27) 1.17 (0.88–1.55) 0.85 (0.62–1.15) 0.96 (0.71–1.30) 0.51
Multivariable I† 1.0 0.92 (0.65–1.29) 1.11 (0.80–1.54) 0.86 (0.60–1.23) 1.00 (0.71–1.42) 0.90
Multivariable II§ 1.0 0.88 (0.61–1.27) 1.08 (0.76–1.54) 0.84 (0.57–1.23) 1.02 (0.70–1.47) 0.96
CHD
n 67 62 76 55 64
Age and smoking adjusted 1.0 0.92 (0.65–1.30) 1.13 (0.81–1.58) 0.82 (0.57–1.18) 1.00 (0.71–1.42) 0.79
Multivariable I† 1.0 0.88 (0.59–1.31) 1.03 (0.70–1.52) 0.82 (0.54–1.24) 0.98 (0.66–1.47) 0.91
Multivariable II§ 1.0 0.85 (0.55–1.32) 1.07 (0.70–1.62) 0.83 (0.53–1.31) 1.03 (0.67–1.59) 0.85
Stroke
n 23 22 28 20 18
Age and smoking adjusted 1.0 1.01 (0.56–1.82) 1.28 (0.73–2.23) 0.93 (0.51–1.70) 0.82 (0.44–1.54) 0.38
Multivariable I† 1.0 1.04 (0.53–2.03) 1.36 (0.71–2.59) 1.00 (0.49–2.02) 1.04 (0.51–2.11) 0.92
Multivariable II§ 1.0 0.97 (0.48–1.94) 1.17 (0.60–2.30) 0.84 (0.41–1.77) 0.94 (0.46–1.95) 0.73
All-cause mortality
Person-years 4,826 4,887 4,858 4,882 4,877
n 112 100 138 95 93
Age and smoking adjusted 1.0 0.91 (0.69–1.19) 1.22 (0.95–1.57) 0.86 (0.65–1.13) 0.94 (0.71–1.24) 0.40
Multivariable I† 1.0 0.91 (0.65–1.29) 1.23 (0.89–1.71) 0.93 (0.65–1.32) 0.80 (0.55–1.16) 0.17
Multivariable II§ 1.0 0.93 (0.63–1.38) 1.30 (0.90–1.87) 0.94 (0.63–1.41) 0.96 (0.64–1.45) 0.70
†Adjusted for age (5-year categories), smoking status (never, past, or current at 1–14 or15 cigarettes/day), BMI (23.0, 23.0–24.9, 25.0–29.9, or30.0 kg/m
2),
alcohol intake (0, 0.1–4.9, 5.0–14.9, or 15 g/day), parental history of myocardial infarction, history of hypertension, hypercholesterolemia, physical activities
(quintiles of METs/week), duration of diabetes (5, 5–10, or 10 years), and hypoglycemic medication (yes or no). ‡Adjusted for the variables cited for model I
anddietaryfactors,includingtotalenergyintake;multivitaminuseandvitaminEsupplementuse;intakeofpolyunsaturated,saturated,andtransfat;long-chainn-3
fatty acids; cereal ﬁber; folate; glycemic load (all in quintiles); and decaffeinated coffee and tea consumption. §Adjusted for the variables cited above except for
decaffeinated coffee and tea consumption.
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(24,121 person-years of follow-up), we
documented 435 cases of incident CVD
(324 CHD and 111 stroke) and 538
deaths from all causes (215 from CHD or
stroke, 145 from cancer, and 178 from
other causes).
In both age- and smoking-adjusted
analyses and multivariable analyses ad-
justing for lifestyle and other cardio-
vascular risk factors, we observed no
association between caffeinated coffee
consumption and a higher risk of CHD,
stroke, or all-cause mortality (Table 1).
Additional adjustment for dietary factors
did not substantially change the results.
Similarly, caffeinated coffee consumption
was not associated with risk of cardiovas-
cular death (relative risks [RRs] 0.64
[95% CI 0.35–1.17] for once per month
to four times per week, 0.84 [0.49–1.44]
for ﬁve to seven times per week, and 0.58
[0.31–1.10] for two or more cups per day
compared with the risks for those who did
not consume caffeinated coffee; P for
trend0.26).Caffeineintakewasnotsub-
stantially associated with CVD or mortality
(Table 1). We also examined decaffeinated
coffee consumption in relation to risk for
CVDandmortalityanddidnotobservesig-
niﬁcant associations (data not shown).
Stratiﬁed analyses showed no direct as-
sociation between coffee consumption and
CVD risk in any subgroups by risk factor
status, including overweight, smoking sta-
tus, duration of diabetes, hypertension, pa-
rental history of myocardial infarction, and
aspirin use (supplemental Table 1, avail-
able in the online appendix [http://care.
diabetesjournals.org/cgi/content/full/dc08-
2251/DC1]).
CONCLUSIONS — In this prospec-
tive study in diabetic men, higher habitual
coffeeconsumptionwasnotassociatedwith
a higher risk of CVD or all-cause mortality.
We did not ﬁnd signiﬁcant associations for
decaffeinated coffee or total caffeine intake
either.
Coffee is a major source of caffeine.
Several studies showed that caffeine
acutely impaired postprandial glucose
metabolism in diabetic patients (8,9). In
addition, concerns have been raised in
short-term trials that caffeine increases
blood pressure (10) and homocysteine lev-
els(11).However,ﬁndingsfromshort-term
caffeine intervention studies cannot be ex-
trapolated to the effects of chronic coffee
consumption on risk of CVD. First, physi-
ological effects of coffee can be different
from those of caffeine. It has been shown
that caffeine results in a larger increase in
epinephrine concentrations than intake of
the same amount of caffeine in coffee (12).
Moreover, coffee contains various sub-
stances such as antioxidants (i.e., chloro-
genic acid) that may improve glucose
metabolism and insulin sensitivity (13).
Second,theacuteeffectsofcaffeinecouldbe
transient because partial tolerance to the
humoral and hemodynamic effects of caf-
feine among habitual drinkers might de-
velop after several days of use (14).
In this study, the availability of up-
dated measures of coffee and covariates
during the follow-up enabled us to incor-
porate changes in coffee consumption
into the analysis. Because coffee drinking
is often thought to be an unhealthy habit,
people may quit or reduce the consump-
tion of coffee to improve their health after
developing hypertension or hypercholes-
terolemia. These changes would dilute a
possible positive association between cof-
fee and CHD or stroke. To reduce this
bias,weexcludedsubjectswithhyperten-
sion or hypercholesterolemia at baseline.
We also conducted a sensitivity analysis
whereweusedshort-termcaffeinatedcof-
fee consumption in relation to CVD and
mortality, which yielded very similar re-
sults. As illustrated by the upper limits of
95% CIs of our RR estimates, we cannot
exclude the possibility that we missed an
association between coffee consumption
and a modestly higher risk of CVD due to
chance. However, results from a previous
studyinFinnishindividualswithdiabetes
support the lack of a direct association
and even suggest an inverse association
between coffee and CVD mortality (5).
In conclusion, in this large prospec-
tive study of U.S. men, our ﬁndings do
not support the hypothesis that habitual
caffeinated coffee consumption increases
risk of cardiovascular events or mortality
among individuals with type 2 diabetes.
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